NCT03443128CompletedPhase 2
Vinorelbine for Recurrent ALCL-2017
Phase II Study of Vinorelbine for Children with Recurrent Anaplastic Large Cell Lymphoma
Source: ClinicalTrials.gov · Last updated 13 Feb 2025
Brief summary (registry, in English)
The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 17 Feb 2018
- Start date
- 1 Nov 2016
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Children's Cancer Group, China
- Diseases
- Childhood cancers
- NCT number
- NCT03443128
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 20
- From 1 Nov 2016 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other systemic diseases, severe infections or critically illness.
Who the study is looking for
- Children and adolescents with a clear diagnosis of recurrent / progressive ALCL at Shanghai Children's Medical Center or other centers since September 2017 include:
- Diagnosed as ALCL, already received first-line treatment, but get disease progression; After receiving ALCL treatment has got CR then diagnosed relapse, need for pathological diagnosis.
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Children's Medical Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.